Diclofenac/misoprostol: Pharmacoeconomic implications of therapy

PharmacoEconomics

Volumn 16, Issue 1, 1999, Pages 85-98

  Plosker, Greg L ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Cost effectiveness; Cost of illness; Diclofenac; Diclofenac misoprostol; Health economics; Misoprostol; NSAID; Osteoarthritis; Pharmacoeconomics; Quality of life; Rheumatoid arthritis

Indexed keywords

DICLOFENAC; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DRUG FORMULARY; DRUG INFORMATION; DRUG UTILIZATION; EPIDEMIOLOGICAL DATA; GASTRODUODENAL ULCER; HEALTH ECONOMICS; HUMAN; MEDICAL LITERATURE; META ANALYSIS; OSTEOARTHROPATHY; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SOCIOECONOMICS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COSTS AND COST ANALYSIS; DICLOFENAC; DRUG COMBINATIONS; DRUG EVALUATION; ECONOMICS, PHARMACEUTICAL; HUMANS; MISOPROSTOL; NEW ZEALAND; PEPTIC ULCER; PROTECTIVE AGENTS;

EID: 0032797990     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916010-00008     Document Type: Review

References (62)

1. 1. Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995 Nov; 7: 372-93
2. 2. Liehtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum 1995 Jan; 38: 5-18
3. 3. Zeidler H. Epidemiology of NSAID-induced gastropathy. Clin Rheumatol 1991 Dec; 10: 369-73
4. 4. Goldstein JL, Larson LR, Yamashita BD. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol. Am J Managed Care 1998; 4: 687-97
5. 5. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 1019-22
6. 6. Agrawal NM. Anti-inflammatories and gastroduodenal damage: therapeutic options. Eur J Rheumatol Inflamm 1993; 13 (1): 17-24
7. 7. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96: 647-55
8. 8. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991 Sep; 91: 213-22
9. 9. Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions: 2. BMJ 1986; 292: 1190-1
10. 10. Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal antiinflammatory drugs. Arthritis Rheum 1991; 34 (11): 1353-60
11. 11. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
12. 12. García Rodríguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998 Mar 30; 104 (3A): 30S-4S
13. 13. Willett LR, Carson JL, Strom BL. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Saf 1994 Feb; 10: 170-81
14. 14. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-63
15. 15. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63
16. 16. Walt R, Katschinski B, Logan R, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986; 1: 489-92
17. 17. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-22
18. 18. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 1535-40
19. 19. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541-6
20. 20. Tannenbaum H, Davis P, Russell AS, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Can Med Assoc J 1996; 155 (1): 77-88
21. 21. Lanza FL. Prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and crosions: a commentary on the new data. Am J Med 1998; 104 (3A): 75S-8S
22. 22. Scheiman J, Isenberg J. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Am J Med 1998; 105 (5A): 32S-8S
23. 23. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: mulitcentre, double-blind, placebo-controlled trial. Lancet 1988 Dec 3; 11: 1277-80
24. 24. Elliott SL, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol 1994; 23: 171-6
25. 25. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119; 257-62
26. 26. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123: 214-49
27. 27. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344-50
28. 28. Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 1991; 28 Suppl.: 11-4
29. 29. de Pouvourville G. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy. Br J Rheumatol 1995; 34 Suppl. I: 19-24
30. 30. Maetzel A, Bosi Ferraz M, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998; 41 (1): 16-25
31. 31. Barradell LB, Whittington R, Benfield P. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. Pharmacoeconomics 1993 Feb; 3: 140-71
32. 32. McKenna F. Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis. Br J Rheumatol 1995 Apr; 34 Suppl. 1: 11-8
33. 33. McKenna F. Diclofenac/misoprostol: the European clinical experience. J Rheumatol 1998; 25 Suppl. 51: 21-30
34. 34. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthrits of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998; 25: 1602-11
35. 35. Bolten W, Melo Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31: 753-8
36. 36. Stead H, Morant SV, Shield MJ. The combination drug diclofenac 75mg/misoprostol 200μg provides equivalent antiarthritic efficacy to diclofenac 75mg SR in RA and OA but with an improved safety profile [abstract]. Rheumatol Eur 1996; 24 Suppl. 3: 220
37. 37. Verdickt W, Moran C, Hantzchel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21: 85-91
38. 38. Bocanegra TS, Kivitz A, Hurley SM, et al. Treatment of osteoarthritis (OA with diclofenac/misoprostol is associated with a lower incidence of gastroduodenal ulcers (GDU) compared to nabumctone and naproxen [abstract no. 985]. Arthritis Rheum 1998; 41 Suppl.: S197
39. 39. Kiff PS, Stead H, Morant V, et al. Arthrotec, diclofenac, and ibuprofen in general practice. Eur J Rheumatol Inflamm 1994; 14 Suppl.: 31-8
40. 40. McKenna F, Allan L, Kiff PS. Diclofenac/misoprostol and indomethacin - efficacy and GI damage in rheumatoid arthritis and ankylosing spondylitis [abstract]. Rheumatol Eur 1995; 24 Suppl. 3: 220
41. 41. Melo Gomes JA, Roth SH, Zech J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993 Dec; 52: 881-5
42. 42. Gabriel SE, Matteson EL. Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis: a conceptual framework and selected literature review. Pharmacoeconomics 1995 Dec; 8: 479-90
43. 43. Gabriel SE, Wagner JL. Costs and effectiveness of nonsteroidal anti-inflammatory drugs: the importance of reducing side effects. Arthritis Care Res 1997 Feb; 10: 56-63
44. 44. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988 Feb 22; 84: 20-4
45. 45. Kendall BJ, Peura DA. NSAID-associated gastrointestinal damage and the elderly. Article five in the series. Pract Gastroenterol 1993; 17: 13-29
46. 46. Gabriel SE, Campion ME, O'Fallon WM, et al. The health care costs of nonsteroidal anti-inflammatory drug-related gastric ulcer in Olmsted County, MN, 1987-1990. Post Market Surveill 1992 Nov; 6: 135-46
47. 47. Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organisation. Pharmacoeconomics 1997; 12 (1): 76-88
48. 48. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997 Aug; 40: 1475-81
49. 49. McCabe CJ, Akehurst RL, Kirsch J, et al. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK. Pharmacoeconomics 1998; 14 (2): 191-9
50. 50. de Pouvourville G. The economic consequences of NSAID induced gastrointestinal damage. Br J Med Econ 1992; 2: 93-102
51. 51. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061-5
52. 52. Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8: 234-44
53. 53. De Pouvourville G. Preventing NSAID-induced gastrointestinal toxicity: economic considerations, methodological problems and results. Pharmacoeconomics 1995 Feb; 7: 99-110
54. 54. Stucki G, Johannesson M, Liang MH. Use of misoprostol in the elderly: is the expense justified? Drugs Aging 1996; 8 (2): 84-8
55. 55. Al MJ, Michel BC, Rutten FFH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996 Aug; 10: 141-51
56. 56. Goldstein JL, Larson LR, Yamashita BD, et al. Management of NSAID-induced gastropathy: an economic decision analysis. Clin Ther 1997 Nov-Dec; 19: 1496-509
57. 57. Goldstein JL, Yamashita BD, Larson LR. Diclofenac/misoprostol vs. PPI prophylaxis in the prevention of NSAID-induced complications: a cost model comparison [abstract]. Gastroenterology 1998; 114: A136
58. 58. Goldstein JL, Stewart D, Zabinski RA, et al. The economic implications of decreased patient adherence to co-prescribed diclofenac and misoprostol (CoRx-D&M) relative to a single-tablet formulation of diclofenac/misoprostol (STF-D/M) [abstract]. Value in Health 1998; 1 (1): 57
59. 59. Annemans L, Vanoverbeke N, Van Rompay W. Cost-effectiveness analysis of a fixed combination (diclofenac + misoprostol) in the prevention of gastropathy in arthritis patients in Belgium [abstract]. Value in Health 1999; 2 (1): 38
60. 60. Sclar DA, Robison LM, Maheu A, et al. Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada. J Int Med Res 1995 Nov-Dec; 23: 439-48
61. 61. Knill-Jones R. An economic evaluation of Arthrotec in the treatment of arthritis. Br J Med Econ 1992; 5: 51-8
62. 62. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14